{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:09:35Z","timestamp":1792145375867,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.berh.2022.101771","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:41:44Z","timestamp":1660351304000},"page":"101771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cancer and myositis: Who, when, and how to screen"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-8634","authenticated-orcid":false,"given":"Sinan","family":"Kardes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2022.101771_bib1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.berh.2022.101771_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2020.10.014","article-title":"Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis","volume":"51","author":"Gupta","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mpmed.2021.10.011","article-title":"Adult idiopathic inflammatory myopathies","volume":"50","author":"Parker","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2022.101771_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.rdc.2019.07.006","article-title":"Idiopathic inflammatory myopathies","volume":"45","author":"Vencovsk\u00fd","year":"2019","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.berh.2022.101771_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib6","first-page":"489","article-title":"Polymyositis","volume":"53","author":"Stertz","year":"1916","journal-title":"Berl Klin Wochenschr."},{"key":"10.1016\/j.berh.2022.101771_bib7","first-page":"335","article-title":"\u00dcber prim\u00e4re nichteitrige Polymyositis","volume":"120","author":"Kankeleit","year":"1916","journal-title":"Dtsch Arch Klin Med"},{"issue":"1","key":"10.1016\/j.berh.2022.101771_bib8","first-page":"9","article-title":"Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark","volume":"6","author":"Chow","year":"1995","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.berh.2022.101771_bib9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.berh.2022.101771_bib10","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2022.101771_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2022.101771_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0025-6196(12)62030-8","article-title":"Polymyositis-dermatomyositis and malignant lesions: does an association exist?","volume":"61","author":"Lakhanpal","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2022.101771_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101771_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.berh.2022.101771_bib15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00296-012-2489-y","article-title":"The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis","volume":"33","author":"Limaye","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2022.101771_bib16","first-page":"1300","article-title":"Elevated cancer incidence in patients with dermatomyositis: a population based study","volume":"22","author":"Airio","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib17","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3899\/jrheum.090549","article-title":"Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA","volume":"36","author":"Antiochos","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101771_bib19","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0049-0172(98)80052-8","article-title":"High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis","volume":"27","author":"Maoz","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib21","first-page":"219","article-title":"Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy","volume":"29","author":"Ang","year":"2000","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.berh.2022.101771_bib22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","article-title":"Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study","volume":"165","author":"Kuo","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib23","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3899\/jrheum.110320","article-title":"Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis","volume":"38","author":"So","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021733","article-title":"Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China","volume":"99","author":"Chang","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2022.101771_bib25","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","article-title":"Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2022.101771_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2020.12.009","article-title":"Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016","volume":"51","author":"Dani","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib27","first-page":"1855","article-title":"The overall and temporal association of cancer with polymyositis and dermatomyositis","volume":"21","author":"Zantos","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.berh.2022.101771_bib29","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A\u00a0systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101771_bib30","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.berh.2022.101771_bib31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1346-8138.2011.01262.x","article-title":"Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients","volume":"38","author":"Ikeda","year":"2011","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2022.101771_bib33","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10067-016-3296-8","article-title":"Malignancy in dermatomyositis and polymyositis: analysis of 192 patients","volume":"35","author":"Fang","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3904\/kjim.2014.29.6.814","article-title":"Complex repetitive discharge on electromyography as a risk factor for malignancy in idiopathic inflammatory myopathy","volume":"29","author":"Kim","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.berh.2022.101771_bib35","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s12253-019-00756-4","article-title":"Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort","volume":"26","author":"Andr\u00e1s","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.berh.2022.101771_bib36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2133.2001.04140.x","article-title":"Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study","volume":"144","author":"Chen","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib37","first-page":"722","article-title":"Facteurs pronostiques et signes pr\u00e9dictifs de cancer au cours de la dermatomyosite de l'adulte [Prognostic factors and predictive signs of malignancy in adult dermatomyositis]","volume":"123","author":"Gallais","year":"1996","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.berh.2022.101771_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-3083.2008.02971.x","article-title":"Clinical and biological factors predictive of malignancy in dermatomyositis","volume":"23","author":"Prohic","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2022.101771_bib39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archderm.138.7.885","article-title":"Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients","volume":"138","author":"Sparsa","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0b013e31819da352","article-title":"Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis","volume":"88","author":"Fardet","year":"2009","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2022.101771_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000051611","article-title":"Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy","volume":"202","author":"Hunger","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2022.101771_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1749-6632.2009.05127.x","article-title":"Epitope specificity and significance in systemic autoimmune diseases","volume":"1183","author":"Mahler","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2022.101771_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101771_bib48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2022.101771_bib50","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2022.101771_bib51","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.berh.2022.101771_bib52","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101771_bib53","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2022.101771_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2022.101771_bib55","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.berh.2022.101771_bib57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2022.101771_bib58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.berh.2022.101771_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2022.101771_bib60","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101771_bib61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101771_bib62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/gyno.1997.4666","article-title":"Serum CA-125 screening for ovarian cancer in patients with dermatomyositis","volume":"65","author":"Whitmore","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.berh.2022.101771_bib63","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1055-9965.EPI-04-0624","article-title":"Tumor antigen markers for the detection of solid cancers in inflammatory myopathies","volume":"14","author":"Amoura","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.berh.2022.101771_bib64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amjmed.2009.11.012","article-title":"Conventional cancer screening versus PET\/CT in dermatomyositis\/polymyositis","volume":"123","author":"Selva-O'Callaghan","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2022.101771_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03707","article-title":"Value of 18F-FDG PET\/CT in the detection of occult malignancy in patients with dermatomyositis","volume":"6","author":"Li","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.berh.2022.101771_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semarthrit.2018.10.021","article-title":"Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis","volume":"49","author":"Kundrick","year":"2019","journal-title":"Semin Arthritis Rheum"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:48Z","timestamp":1761499308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1521694222000304"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101771","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer and myositis: Who, when, and how to screen","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101771"}}